Salarius Pharmaceuticals, Inc. (SLRX) Q1 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the first quarter 2022 Solaris Pharmaceuticals Earnings Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one on your telephone. Please be advised that today's conference is being recorded. If you require assistance during the conference, please press star zero. I would now like to hand the conference over to your speaker today, Daniel Canto-Boateng. Good afternoon, and thank you for joining Solaris Pharmaceuticals' 2022 First Quarter Financial and Corporate Results Call. This afternoon, Solaris Pharmaceuticals issued a press release detailing its financial results for the three months ended March 31, 2022, which we encourage listeners to read. The press release can be found in the news section of solarisfarma.com. Before beginning today's call, I would like to make the following statement. Today, we will be making certain forward-looking statements about operating metrics, future expectations, plans, events, and circumstances, including statements about our strategy, future operations, the development and effectiveness of our investigational drug candidates, Secodemstat, and SP3164, as well as our targeted protein degradation program and expectations regarding our capital allocation and cash resources, as well as asking shareholders to vote before or during the 2022 Annual Stockholders Meeting taking place on June 15, 2022. These statements are based on our current expectations, and you should not place undue reliance on these statements. Actual results may differ materially due to our risk and uncertainties, including those detailed in th...